-
11:21:28 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

AZN Stock News

10/20/21 9:00 AM
Nasdaq : AZN
AstraZeneca Announces Winners and Recognizes Oncology Change Makers in Third Annual Cancer Community Awards
AstraZeneca, in partnership with Scientific American Custom Media, today announced the winners of the third annual Cancer Community Awards. “As we commemorate 50 years since the National Cancer Act was signed and reflect upon the extraordinary progress made in treating this disease, we are inspired by this year’ s winners and finalists,” said Chatrick Paul, Head...
RHEA-AI
positive
10/15/21 7:00 AM
Nasdaq : AZN
IMFINZI Plus Tremelimumab Significantly Improved Overall Survival in HIMALAYA Phase III Trial in 1st-Line Unresectable Liver Cancer
Positive high-level results from the HIMALAYA Phase III trial showed a single, high priming dose of tremelimumab added to IMFINZI ® demonstrated a statistically significant and clinically meaningful overall survival benefit versus sorafenib as a 1st- line treatment for patients with unresectable hepatocellular carcinoma who had not received prior...
RHEA-AI
negative
10/04/21 7:00 AM
Nasdaq : AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Granted Breakthrough Therapy Designation in US for Patients with HER2-Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based Regimens
The Food and Drug Administration has granted ENHERTU ® Breakthrough Therapy Designation in the US for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens. ENHERTU is a HER2-directed antibody drug conjugate jointly developed by AstraZeneca and...
RHEA-AI
neutral
09/29/21 7:00 AM
Nasdaq : AZN
AstraZeneca Healthcare Foundation Awards Seven US Nonprofits More Than $900k to Improve Heart Health and Advance Health Equity
Today on World Heart Day, the AstraZeneca HealthCare Foundation has awarded seven innovative, community-based nonprofit organizations $954,311 in grants across seven US states to address cardiovascular disease, a leading cause of death in the nation. The grants are part of the Foundation’ s signature Connections for Cardiovascular Health SM Next...
RHEA-AI
positive
09/27/21 7:00 AM
Nasdaq : AZN, VACC
covid-19
AstraZeneca COVID-19 and RSV presentations at IDWeek 2021 will showcase scientific progress in infectious diseases
AstraZeneca will present data across its COVID-19 and respiratory syncytial virus pipeline at the 10 th Annual IDWeek Virtual Conference, September 29 to October 3, 2021, illustrating its commitment to advancing innovative science in infectious diseases. Data featuring AstraZeneca’ s investigational long-acting antibody programs– AZD7442 for...
RHEA-AI
neutral
09/24/21 6:45 AM
Nasdaq : AZN
LYNPARZA® (olaparib) in combination with abiraterone significantly delayed disease progression in all-comers in PROpel Phase III trial in 1st-line metastatic castration-resistant prostate cancer
AstraZeneca and Merck& Co., Inc., known as MSD outside the US and Canada, today announced positive high-level results from the PROpel Phase III trial. LYNPARZA ® in combination with abiraterone demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival versus standard-of-care...
RHEA-AI
neutral
09/18/21 11:30 AM
Nasdaq : AZN
IMFINZI Plus Chemotherapy Tripled Patient Survival at Three Years in the CASPIAN Phase III Trial in Extensive-Stage Small Cell Lung Cancer
Updated results from the CASPIAN Phase III trial showed AstraZeneca’ s IMFINZI ® in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival benefit at three years for adults with extensive-stage small cell lung cancer treated in the 1st- line setting.
RHEA-AI
negative